Screener
Aclaris Therapeutics ACRS Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Payments of employee withholding taxes related to restricted stock unit award vesting | (273) | (284) |
| Proceeds from exercise of employee stock options and the issuance of stock | 265 | — |
| Net cash provided by (used in) financing activities | 57,872 | (284) |
| Net (decrease) increase in cash and cash equivalents | (793) | 832 |
| Cash and cash equivalents at beginning of period | 19,960 | 24,570 |
| Cash and cash equivalents at end of period | $19,167 | $25,402 |
| Supplemental disclosure of non-cash investing activities: | ||
| Additions to property and equipment included in accounts payable | $3 | — |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's net change in cash?
- Aclaris Therapeutics (ACRS) reported net change in cash of -$9.49M in Q2 2026.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Aclaris Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude